WilmerHale Successfully Represents Fabre-Kramer Pharmaceuticals in Collaboration with GlaxoSmithKline

Download IconDownload Print IconPrint

WilmerHale Successfully Represents Fabre-Kramer Pharmaceuticals in Collaboration with GlaxoSmithKline

Client News

Related Solutions

We leverage technical knowledge, business acumen and legal experience to structure, prepare and negotiate innovative and effective technology-related agreements.

WilmerHale successfully represented its client Fabre-Kramer Pharmaceuticals in its worldwide development and commercialization agreement with GlaxoSmithKline for Fabre-Kramer's gepirone ER product, a 5HT1a agonist expected to be submitted in the first quarter of 2007 for FDA review in the US for major depressive disorder (MDD). Under the terms of the agreement, Fabre-Kramer Pharmaceuticals will receive an upfront cash payment followed by additional development and commercialization milestone payments and double-digit percentage royalty payments on worldwide sales of gepirone ER and follow-on products. In return, GlaxoSmithKline was granted an exclusive, worldwide license to develop, manufacture and commercialize gepirone ER and follow-on products.

The WilmerHale lawyers working on the transaction included David Redlick, Steven Barrett, Allison May and James Czaban.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel